introduct
recent
outbreak
sever
acut
respiratori
syndrom
sar
warrant
search
effect
antivir
agent
treat
diseas
studi
describ
assess
antivir
potenti
nitric
oxid
sar
coronaviru
sarscov
strain
replic
african
green
monkey
vero
cell
result
two
organ
donor
compound
snitrosonacetylpenicillamin
snap
sodium
nitroprussid
snp
test
broad
rang
concentr
nonnitrosyl
form
snap
nacetylpenicillamin
nap
includ
control
compound
assay
antivir
activ
estim
inhibit
sarscov
cytopath
effect
vero
cell
determin
tetrazoliumbas
colorimetr
method
cytotox
compound
test
parallel
conclus
surviv
rate
sarscov
infect
cell
greatli
increas
treatment
snap
concentr
compound
need
inhibit
viral
cytopath
effect
select
index
antisarscov
effect
could
detect
snp
nap
sever
acut
respiratori
syndrom
sar
recent
emerg
new
sever
human
diseas
result
global
death
report
probabl
case
septemb
novel
member
coronavirida
famili
identifi
caus
agent
pulmonari
diseas
thu
far
treatment
sar
case
larg
empir
usual
includ
antivir
agent
ribavirin
combin
lopinavirritonavir
steroid
howev
unclear
whether
treatment
abl
alter
ultim
outcom
diseas
sar
epidem
chen
colleagu
includ
inhal
ga
treatment
number
sar
patient
medicin
ga
gaseou
blend
nitric
oxid
nitrogen
given
three
day
longer
initi
ppm
ppm
second
third
day
unpublish
data
find
suggest
immedi
improv
oxygen
also
last
effect
diseas
termin
inhal
key
molecul
pathogenesi
infecti
diseas
varieti
microbi
infect
biosynthesi
occur
express
induc
nitric
oxid
synthas
ino
molecul
report
antivir
effect
varieti
dna
rna
virus
includ
mous
hepat
viru
mhv
murin
coronaviru
recent
studi
replic
two
sarscov
isol
shown
greatli
inhibit
glycyrrhizin
activ
compound
liquoric
root
glycyrrhizin
upregul
express
ino
product
macrophag
although
initi
global
outbreak
sar
appear
success
contain
sar
remain
seriou
concern
continu
suitabl
vaccin
effect
drug
treatment
studi
examin
antivir
activ
nitric
oxid
sar
coronaviru
sarscov
isol
two
donor
compound
snitrosonacetylpenicillamin
snap
sigma
belgium
sodium
nitroprussid
snp
sigma
belgium
ad
confluent
african
green
monkey
vero
cell
snap
releas
aqueou
solut
halflif
approxim
hour
nonnitrosyl
form
snap
nacetylpenicillamin
nap
sigma
belgium
includ
control
compound
assay
antivir
activ
cytotox
measur
base
viabil
cell
infect
infect
ccid
cell
cultur
infect
dose
sarscov
presenc
variou
concentr
test
compound
three
day
infect
number
viabl
cell
quantifi
tetrazoliumbas
colorimetr
method
reduct
mt
dye
celltit
aq
ueou
one
solut
kit
promega
netherland
cellular
dehydrogenas
insolubl
colour
formazan
measur
spectrophotomet
multiskan
ex
thermo
labsystem
belgium
nm
select
index
determin
ratio
concentr
compound
reduc
cell
viabil
cc
cytotox
concentr
concentr
compound
need
inhibit
viral
cytopath
effect
control
valu
ic
inhibitori
concentr
amount
produc
snap
cultur
medium
determin
assay
stabl
endproduct
nitrit
cell
cultur
environ
freezethaw
cell
cultur
sampl
centrifug
g
min
equal
volum
l
sampl
supernat
griess
reagent
sulphanilamid
h
po
sigma
belgium
mix
incub
min
c
optic
densiti
nm
measur
autom
multiscan
spectrophotomet
rang
sodium
nitrit
dilut
serv
gener
standard
curv
assay
snap
inhibit
sarscov
replic
nontox
concentr
select
index
tabl
concentr
releas
snap
protect
effect
cc
could
demonstr
snp
differ
activ
two
donor
compound
might
explain
differ
mechan
releas
snap
direct
donor
gener
aqueou
solut
hydrolysi
snp
releas
reaction
reduc
agent
protect
effect
could
obtain
nacetylpenicillamin
nap
nonnitrosyl
form
snap
releas
solut
figur
result
illustr
protect
effect
snap
consequ
releas
potenti
solitari
antivir
effect
nacetylpenicillamin
moieti
studi
provid
addit
evid
nodonor
may
antivir
effect
sarscov
specul
prolong
effect
inhal
ga
observ
earlier
could
antivir
effect
sarscov
base
result
encourag
inclus
inhal
treatment
sar
nodonor
includ
snap
describ
potenti
therapeut
treatment
cardiovascular
diseas
confirm
antisarscov
effect
ga
donor
snap
use
sar
treatment
addit
vivo
experi
requir
resurg
sar
outbreak
distinct
possibl
search
antivir
effect
sarscov
remain
import
endeavour
